Core Viewpoint - Neogen (NEOG) shares have increased by 11.7% in the past four weeks, closing at $6.29, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $8.17, representing a 29.9% upside [1] Price Targets - The average price targets range from a low of $6.50 to a high of $10.00, with a standard deviation of $1.76, indicating variability among analysts [2] - The lowest estimate suggests a 3.3% increase, while the highest estimate indicates a 59% upside [2] Analyst Consensus and Earnings Estimates - Analysts show a strong agreement in revising earnings estimates higher, which historically correlates with stock price movements [4][11] - The Zacks Consensus Estimate for the current year has increased by 50% over the past month, with no negative revisions [12] - NEOG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Group 1 - Rithm (RITM) shares have increased by 1.6% over the past four weeks, closing at $11.07, with a mean price target of $14.14 indicating a potential upside of 27.7% [1] - The mean estimate consists of seven short-term price targets with a standard deviation of $1.11, where the lowest estimate is $12.50 (12.9% increase) and the highest is $16.00 (44.5% increase) [2] - Analysts show strong agreement on RITM's ability to report better earnings, with a positive trend in earnings estimate revisions suggesting potential upside [4][11] Group 2 - The Zacks Consensus Estimate for RITM's current year has increased by 1.2% over the last 30 days, with one estimate moving higher and no negative revisions [12] - RITM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of RITM's potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - Apogee Therapeutics Inc. (APGE) has seen a significant stock price increase of 41.4% over the past four weeks, closing at $55.7, with analysts suggesting a potential upside of 69.3% based on a mean price target of $94.3 [1][11]. Price Targets and Analyst Estimates - The mean estimate for APGE comprises 10 short-term price targets with a standard deviation of $16.3, indicating variability among analysts. The lowest estimate suggests a 7.7% increase to $60.00, while the highest estimate predicts a surge of 108.3% to $116.00 [2][9]. - A tight clustering of price targets, represented by a low standard deviation, indicates a high degree of agreement among analysts regarding the stock's price movement direction [9]. Earnings Estimates and Analyst Agreement - Analysts show strong agreement in revising earnings per share (EPS) estimates higher for APGE, which is a positive indicator for potential stock upside. This correlation between earnings estimate revisions and stock price movements is supported by empirical research [4][11]. - Over the past 30 days, one estimate for APGE has increased, leading to a 0.9% rise in the Zacks Consensus Estimate, with no negative revisions noted [12]. Zacks Rank and Investment Potential - APGE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, which further supports its potential upside [13]. - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a useful guide for the direction of price movement [14].

Core Viewpoint - Ocular Therapeutix (OCUL) shares have increased by 4% recently, with a mean price target of $21 indicating a potential upside of 82.9% from the current price of $11.48 [1] Price Targets and Analyst Estimates - The mean estimate consists of 12 short-term price targets with a standard deviation of $4.92, suggesting variability in analyst predictions [2] - The lowest estimate of $14.00 indicates a 22% increase, while the highest estimate suggests a 170% surge to $31.00 [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] Earnings Estimates and Analyst Agreement - There is strong agreement among analysts regarding OCUL's ability to report better earnings, which supports the potential for stock upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 5.4%, with four estimates moving higher and no negative revisions [12] - OCUL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While consensus price targets may not be reliable for predicting the extent of OCUL's gains, they can provide a directional guide for potential price movement [14]

Group 1 - Oruka Therapeutics, Inc. (ORKA) shares have increased by 42.7% in the past four weeks, closing at $27.44, with a mean price target of $44.89 indicating a potential upside of 63.6% [1] - The average price target from nine analysts ranges from a low of $26.00 to a high of $60.00, with a standard deviation of $9.82, suggesting variability in estimates [2] - Analysts show strong agreement on ORKA's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for ORKA has increased by 1.1% due to one upward revision in earnings estimates over the last 30 days, with no negative revisions [12] - ORKA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [14]

Core Viewpoint - Tamboran Resources Corporation (TBN) has seen a 25.8% increase in share price over the past four weeks, closing at $26.61, with a potential upside of 42.8% based on Wall Street analysts' mean price target of $38 [1]. Price Targets - The average price target consists of five estimates ranging from a low of $32.00 to a high of $42.00, with a standard deviation of $3.94, indicating a potential increase of 20.3% to 57.8% from the current price level [2]. - A low standard deviation suggests a strong agreement among analysts regarding the price targets, which can be a useful indicator for investors [2][9]. Analyst Sentiment - Analysts show strong agreement on TBN's ability to report better earnings than previously predicted, which supports the view of potential upside [4]. - The Zacks Consensus Estimate for the current year has increased by 3.2% over the past month, with no negative revisions, indicating positive sentiment among analysts [12]. Zacks Rank - TBN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, which further indicates potential upside in the near term [13]. Conclusion on Price Movement - While consensus price targets may not be entirely reliable, the direction implied by these targets appears to be a good guide for potential price movement [14].

Core Viewpoint - Shares of Amylyx Pharmaceuticals, Inc. (AMLX) have increased by 3.6% over the past four weeks, closing at $14.31, with a potential upside indicated by Wall Street analysts' mean price target of $18.5, suggesting a 29.3% increase [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $3.85, where the lowest estimate is $12.00 (indicating a 16.1% decline) and the highest is $25.00 (indicating a 74.7% increase) [2] - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price movement [2][9] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about AMLX's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 8.8% over the past month, with two estimates increasing and no negative revisions [12] Zacks Rank and Investment Potential - AMLX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [13] - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a useful guide for potential investment [14]

Core Viewpoint - Cognizant (CTSH) shows potential for significant upside, with a mean price target of $85.5 indicating a 25.7% increase from the current price of $68.03 [1] Price Targets and Analyst Estimates - The mean estimate consists of 20 short-term price targets, with a standard deviation of $8.79, indicating variability among analysts [2] - The lowest estimate is $70.00, suggesting a 2.9% increase, while the highest estimate is $103.00, indicating a potential surge of 51.4% [2] - A low standard deviation signifies a high degree of agreement among analysts regarding price movement direction [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about CTSH's earnings prospects, with a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.2%, with one estimate moving higher and no negative revisions [12] - CTSH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8] - Investors should treat price targets with skepticism and not rely solely on them for investment decisions [10]

Core Viewpoint - Dutch Bros (BROS) shares have increased by 7.1% in the past four weeks, closing at $57.14, with a potential upside of 38.9% based on Wall Street analysts' mean price target of $79.38 [1][4]. Price Targets and Analyst Estimates - The mean estimate consists of 16 short-term price targets with a standard deviation of $8.48, indicating variability among analysts [2]. - The lowest estimate is $65.00, suggesting a 13.8% increase, while the highest estimate is $95.00, indicating a potential surge of 66.3% [2]. - A low standard deviation signifies a high degree of agreement among analysts regarding the stock's price movement [9]. Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about BROS's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11]. - Over the last 30 days, one estimate has increased, leading to a 0.7% rise in the Zacks Consensus Estimate [12]. - BROS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13]. Caution on Price Targets - Solely relying on price targets for investment decisions may not be prudent, as analysts' ability to set accurate targets has been questioned [3][10]. - Price targets can often be inflated due to business incentives, leading to overly optimistic projections [8].

Core Viewpoint - Orla Mining Ltd. (ORLA) shows potential for significant upside, with a mean price target of $16.31 indicating a 49% increase from its current price of $10.95 [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $2.98, suggesting a range of estimates from $12.89 (17.7% increase) to $19.95 (82.2% increase) [2][4]. - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction [9]. Earnings Estimates and Revisions - Analysts have shown increasing optimism about ORLA's earnings, with four estimates revised higher in the last 30 days and no negative revisions, leading to a 17.2% increase in the Zacks Consensus Estimate [12][11]. - The correlation between earnings estimate revisions and near-term stock price movements supports the expectation of an upside in ORLA's stock [11]. Zacks Rank and Investment Potential - ORLA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13]. - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14].